Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.89 USD | -0.81% | +12.14% | 0.00% |
Apr. 30 | Morgan Stanley Starts Contineum Therapeutics With Overweight Rating | MT |
Apr. 30 | Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 15M | Capitalization | 403M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 99.6M | Net cash position 2025 * | 53.37M | EV / Sales 2025 * | 23.3 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.81% |
1 day | -0.81% | ||
1 week | +12.14% | ||
Current month | +1.28% | ||
1 month | +7.12% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 15.74 | -1.72% | 47 224 |
24-05-09 | 16.02 | +2.10% | 147,228 |
24-05-08 | 15.69 | +5.94% | 114,226 |
24-05-07 | 14.81 | -0.07% | 77,411 |
24-05-06 | 14.82 | +5.18% | 34,593 |
Delayed Quote Nasdaq, May 10, 2024 at 12:42 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 403M | |
+18.55% | 47.02B | |
+48.77% | 41.86B | |
+0.28% | 41.76B | |
-4.27% | 28.8B | |
+11.66% | 26.05B | |
-22.04% | 19.15B | |
+4.59% | 12.55B | |
+29.66% | 12.34B | |
-4.30% | 11.82B |
- Stock Market
- Equities
- CTNM Stock